S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Cyclo Therapeutics Stock Forecast, Price & News

-0.02 (-0.38%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
61,357 shs
Average Volume
448,118 shs
Market Capitalization
$34.08 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CYTH News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product candidates include Trappsol Cyclo, which treats Neimann-Pick Type C disease. The firm focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.


Cyclo Falls After IPO
November 17, 2021 |  baystreet.ca
Cyclo Therapeutics (NASDAQ:CYTH) Issues Earnings Results
November 16, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industrial organic chemicals
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$900 thousand
Book Value
$1.18 per share


Net Income
$-8.94 million
Net Margins
Pretax Margin




Free Float
Market Cap
$34.08 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.20 out of 5 stars

Medical Sector

377th out of 1,391 stocks

Industrial Organic Chemicals Industry

10th out of 23 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Cyclo Therapeutics (NASDAQ:CYTH) Frequently Asked Questions

Is Cyclo Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclo Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cyclo Therapeutics stock.
View analyst ratings for Cyclo Therapeutics
or view top-rated stocks.

When is Cyclo Therapeutics' next earnings date?

Cyclo Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022.
View our earnings forecast for Cyclo Therapeutics

How were Cyclo Therapeutics' earnings last quarter?

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) issued its quarterly earnings data on Sunday, November, 14th. The company reported ($0.60) earnings per share for the quarter, topping analysts' consensus estimates of ($0.67) by $0.07. The company had revenue of $0.40 million for the quarter. Cyclo Therapeutics had a negative trailing twelve-month return on equity of 130.26% and a negative net margin of 1,236.82%.
View Cyclo Therapeutics' earnings history

What price target have analysts set for CYTH?

1 brokers have issued 12-month price objectives for Cyclo Therapeutics' stock. Their forecasts range from $16.00 to $16.00. On average, they anticipate Cyclo Therapeutics' stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 203.0% from the stock's current price.
View analysts' price targets for Cyclo Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Cyclo Therapeutics' key executives?

Cyclo Therapeutics' management team includes the following people:

What is Cyclo Therapeutics' stock symbol?

Cyclo Therapeutics trades on the NASDAQ under the ticker symbol "CYTH."

Who are Cyclo Therapeutics' major shareholders?

Cyclo Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.80%), UBS Group AG (0.62%), BlackRock Inc. (0.20%) and Two Sigma Advisers LP (0.19%). Company insiders that own Cyclo Therapeutics stock include Francis Patrick Ostronic, Jeffrey Tate, Joshua M Fine, Markus Sieger, N Scott Fine and Sharon Hemond Hrynkow.
View institutional ownership trends for Cyclo Therapeutics

Which major investors are buying Cyclo Therapeutics stock?

CYTH stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, Two Sigma Advisers LP, Geode Capital Management LLC, and BlackRock Inc.. Company insiders that have bought Cyclo Therapeutics stock in the last two years include Francis Patrick Ostronic, Jeffrey Tate, Joshua M Fine, Markus Sieger, N Scott Fine, and Sharon Hemond Hrynkow.
View insider buying and selling activity for Cyclo Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Cyclo Therapeutics?

Shares of CYTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cyclo Therapeutics' stock price today?

One share of CYTH stock can currently be purchased for approximately $5.28.

How much money does Cyclo Therapeutics make?

Cyclo Therapeutics has a market capitalization of $34.08 million and generates $900 thousand in revenue each year.

How many employees does Cyclo Therapeutics have?

Cyclo Therapeutics employs 8 workers across the globe.

What is Cyclo Therapeutics' official website?

The official website for Cyclo Therapeutics is www.ctd-holdings.com.

Where are Cyclo Therapeutics' headquarters?

Cyclo Therapeutics is headquartered at 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653.

How can I contact Cyclo Therapeutics?

Cyclo Therapeutics' mailing address is 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653. The company can be reached via phone at (386) 418-8060, via email at [email protected], or via fax at 321-244-8351.

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.